This brochure gives an overview of the care and support services NPUK offers.
File size: 4 MB Download
The NPUK Fundraising Guide tells you everything you need to know about raising donations for Niemann-Pick UK!
File size: 4 MB Download
The work of Dr Tarekegn Geberhiwot, and the many expert professionals involved in creating the INPDR has resulted in 'The Consensus Clinical Management Guidelines for NP-C', which provides an excellent resource for the wider NPD community.
File size: 917 KB Download15.03.19
ALACHUA, FL – (Globe Newswire) – March 14, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer’s Disease. The trial will use Trappsol® Cyclo™, the company’s proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously.
Read more11.03.19
IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC): OXFORD, UK, March 11, 2019-- IntraBio Inc., a late-stage biopharmaceutical company, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) Application for Clinical Trial IB1001-201 with its lead compound (IB1001) for the treatment of Niemann-Pick disease Type C (NPC).
Read more
